December 2019

Financial Times features INMUNOTEK as an example of a Spanish company with strong growth along the years even in unfavorable situations. According to the economic newspaper, the strength of these companies is based on their commitment to innovation and competitiveness. This allows to focus its productive activity towards foreign markets, have a sustained growth and create employment.
More info

December 2019

myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and INMUNOTEK announced a collaboration to develop an Expanded Access Program (EAP) for the unlicensed bacterial vaccine Uromune.
More info

November 2019

The Spanish Ministry of Science, Innovation and Universities has awarded INMUNOTEK the National Innovation Award 2019. This price, the highest award granted in Spain to distinguish companies that make innovation their main business growth strategy, is endowed with 30,000 euros and has been granted to INMUNOTEK in the category of "Small and Medium-Sized Enterprise".
More info

November 2019

INMUNOTEK has been awarded as the Best SME of the Year 2019 by CEPYME (Spanish Confederation of Small and Medium-Sized Enterprises). This award recognizes Business Excellence under the criteria of business activity, innovation, internationalization and job creation. The award ceremony was chaired by the Spanish Minister of Economy and Business, Nadia Calviño, the President of CEPYME, Gerardo Cuerva and the CEO of Santander Bank, Rami Aboukhair, as sponsor of the award.
More info

June 2019

INMUNOTEK has been present at the EAACI congress held in Lisbon in the commercial exhibition area. The annual conference of the EAACI (European Academy of Allergy and Clinical Immunology) is one of the most important events in the field of allergy and immunology worldwide. With a participation of more than 7,000 delegates and a high scientific and commercial level, the annual congress is the most outstanding event of the EAACI.
More info